The Power of Debate
Debates hold transformative power in the field of rheumatology and autoimmunity, offering an unparalleled platform to challenge established norms and ignite forward-thinking ideas. At CORA 2025, attendees can dive into 21 dynamic debates, each designed to address some of the most pivotal and thought-provoking issues in rheumatology today. This unique format brings together leading experts to argue opposing views on urgent clinical, diagnostic, and therapeutic questions. The debates stimulate critical thinking, inspire innovative approaches, and ultimately push the field towards more effective patient-centered solutions.
What Should We Use As the First-Line Treatment for RA?
Debate 1
Zoltan Szekanecz (Hungary)
b/tsDMARDs
Andrea Rubbert-Roth (Switzerland)
MTX
Are the New Classification Criteria a Step Forward in the Management of Antiphospholipid Syndrome?
Debate 2
Savino Sciascia (Italy)
Yes
Jaume Alijotas-Reig (Spain)
No
LN Treatment: Early Combination vs. Standard Treatment
Debate 3
Ioannis Parodis (Sweden)
Early Combination
Laurent Arnaud (France)
Standard Treatment
The Use of Medical Cannabis in Rheumatic Pain Management: Valid Option or Unproven Treatment?
Debate 4
Howard Amital (Israel)
Valid Option
Winfried Häuser (Germany)
Unproven Treatment
Beyond Physical Examination – How to Approach to RA Management: Joint Ultrasound or Synovial Biopsy?
Debate 5
Maria-Antonietta D’Agostino (Italy)
Joint Ultrasound
Felice Rivellese (United Kingdom)
Synovial Biopsy
Mepolizumab in EGPA: Does One Size Fit All?
Debate 6
Benjamin Terrier (France)
Yes
Giacomo Emmi (Italy)
No
TNFi or IL17i for the Slowing the Radiographic Progression in Spondyloarthritis?
Debate 7
Mikkel Østergaard (Denmark)
TNFi
Salvatore D’Angelo (Italy)
IL17i
Gut Microbiome in Rheumatic Diseases: Revolutionary or Fake News?
Debate 8
Francesco Ciccia (Italy)
Revolutionary
Zoltan Szekanecz (Hungary)
Fake News
CAR-T Cells in Rheumatic Diseases: Game-Changer or Just a Buzz?
Debate 9
Laura Bucci (Germany)
Game-Changer
Marit Stockfelt (Sweden)
Just a Buzz
Is Seronegative Sjogren Syndrome a Distinct Clinical Entity? & Should Hydroxychloroquine Be Used in Patients With Sjogren Syndrome?
Debate 10
Roberto Gerli (Italy)
Yes
Athanasios Tzioufas (Greece)
No
Early Biologic Treatment in Systemic Lupus: Necessary or Overemphasized?
Debate 11
Mariele Gatto (Italy)
Necessary
Chris Wincup (UK)
Overemphasized
Is Hematopoietic Stem Cell Transplantation (Really) a Valid Option for Patients with Systemic Sclerosis?
Debate 12
Dominique Farge (France)
Yes
Oliver Distler (Switzerland)
No
Can We Give Targeted Therapies in Patients With Cancer?
Debate 13
Eden Sebbag (France)
Yes
Zoltan Szekanecz (Hungary)
No
Are IPAF and UCTD Two Clinical Variants of the Same Systemic Autoimmune Disorder?
Debate 14
Marco Sebastiani (Italy)
Two Clinical Variants
Szilvia Szamosi (Hungary)
The Same
Do JAK Inhibitors Aggravate Comorbidities Such As Cardiovascular Disease and Cancer?
Debate 15
Serena Bugatti (Italy)
Yes
Ernest Choy (UK)
No
Should We Treat preRA/at Risk RA Individuals or Not?
Debate 16
Andrew Cope (UK)
Yes
György Nagy (Hungary)
No
Is It Common To Achieve the T2T goals in SLE Patients?
Debate 17
Marta Mosca (Italy)
Yes
Anisur A. Rahman (UK)
No
Axial Psoriatic Arthritis and axSpA: To Lump or to Split
Debate 18
Phillip Sewerin (Germany)
To Lump
Ennio Lubrano (Italy)
To Split
Should Immunosuppressive Drugs be Used in All Patients With the Limited Cutaneous Form of SSc?
Debate 19
Marco Matucci-Cerinic (Italy)
Yes
Yannick Allanore (France)
No
Is It Safe to Use Low-Dose Glucocorticoids in GCA?
Debate 20
Francesco Muratore (Italy)
Yes
Peter Villiger (Switzerland)
No
Transition from Psoriasis to Psoriatic Arthritis: Are We getting Closer?
Debate 21
Alen Zabotti (Italy)
Yes
Dennis McGonagle (UK)
No